207
views
1
recommends
+1 Recommend
1 collections
    2
    shares
      scite_
       
      • Record: found
      • Abstract: found
      • Conference Proceedings: found
      Is Open Access

      2D- and 3D printed drugs

      Published
      proceedings-article
        1 ,
      ScienceOpen
      RExPO22
      2-3 September, 2022
      Personalized Medicine, 3D Printing, Clinical Samples, Drug Repurposing, REPO4EU
      Bookmark

            Abstract

            Until now, medicinal products and clinical trial samples have been made available at great expense either by the pharmaceutical industry or by appropriately qualified clinical pharmacies. From a legal point of view, it is relevant that a system consisting of hardware (GMP-compliant printers and in-process controls) as well as software and inks containing active ingredients (2D printing) or polymers (3D printing) is developed and made available. This system must be coordinated and validated. Through the technology of GMP-compliant 2D and 3D printing, it is now possible to produce clinical trial samples including the production of corresponding placebos. The advantage of digital printing of medicinal products and clinical trial samples lies above all in the dosage, which can be flexibly changed at any time, the rapid production on site and the flexible combination of active ingredients in a printed tablet. This means that in clinical trials, such as targeted drug repurposing, or in everyday clinical practice, the drug can now be produced in exactly the dose that is really needed individually. In addition, drugs can be individually printed in a tablet so that each patient receives the tablet in the appropriate dose that he or she really needs. Furthermore, only what is actually used is produced, and the creation of unnecessary pharmaceutical waste is prevented. The process is resource-saving. The aim is that this technology, developed in Europe on the REPO4EU platform, will be able to demonstrate its advantages for the production of clinical trial samples and will be used routinely.

            Content

            Author and article information

            Conference
            ScienceOpen
            15 August 2022
            Affiliations
            [1 ] DIHESYS, Digital Health Systems, Schwaebisch Gmuend, Germany
            Author notes
            Author information
            https://orcid.org/0000-0002-2483-7249
            Article
            10.14293/S2199-1006.1.SOR-.PPP3LBTQ.v1
            0f00ce46-e22f-4508-bd54-03c05789d015

            This work has been published open access under Creative Commons Attribution License CC BY 4.0 , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Conditions, terms of use and publishing policy can be found at www.scienceopen.com .

            RExPO22
            Maastricht, Netherlands
            2-3 September, 2022
            History
            : 15 August 2022

            The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
            3D Printing,Clinical Samples,Drug Repurposing,REPO4EU,Personalized Medicine

            Comments

            Comment on this article